Drug Profile

Itraconazole inhaled - Cipla/Pulmatrix

Alternative Names: Itraconazole Powder; Pulmazole; PUR 1900

Latest Information Update: 28 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pulmatrix
Class Antiasthmatics; Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Dioxoles; Piperazines; Small molecules; Triazoles
Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell signalling pathway inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Aspergillosis
New Molecular Entity No

Highest Development Phases

Phase II Aspergillosis; Asthma

Most Recent Events

15 May 2025 Central Drug Standard Control Organization approves application for Itraconazole inhaled for phase III trial
15 May 2025 Cipla plans a phase III trial for Aspergillosis in India
13 Nov 2024 Pulmatrix plans a merger with Cullgen in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com